REM sleep latency and neurocognitive dysfunction in schizophrenia.
BACKGROUND
Cognitive deficits-the hallmark of schizophrenic deterioration-still remain elusive as far as their pathophysiology is concerned. Various neurotransmitter systems have been implicated to explain these deficits. Abnormalities in cholinergic neurotransmission in the brain are one of the postulations; acetylcholine has also been postulated to regulate rapid eye movement (REM) sleep, especially REM latency. Thus, REM latency in patients with schizophrenia might provide a non-invasive window to look into the cholinergic functions of the brain.


OBJECTIVE
To study REM sleep measures and neurocognitive function in schizophrenia, and the changes occurring in these parameters following pharmacological treatment.


METHODS
Thirty subjects (15 with schizophrenia and 15 normal non-relative controls) were evaluated in this study. Most patients with schizophrenia had prominent negative symptoms and deficits in the performance in neurocognitive tests battery. They were treated with antipsychotics for a variable period of time and post-treatment evaluation was done using the same battery of neurocognitive tests and polysomnography. Patients were either drug-naïve or kept drug-free for at least two weeks both at baseline as well as at the post-treatment stage.


RESULTS
A positive correlation between the severity of negative symptoms and neurocognitive deficits (especially on the Wisconsin Card Sorting), and a negative correlation between these two parameters and REM latency was observed.


CONCLUSIONS
It can be hypothesized that the acetylcholine deficit model of dementia cannot be applied to schizophrenic dementia, rather a hypercholinergic state results. This state warrants anticholinergic medication as a treatment option for negative symptoms of schizophrenia.
Das
Mrinmay
M
Consultant Psychiatrist, Department of Psychiatry and Drug De-addiction Centre, Lady Hardinge Medical College and Associated Hospitals, New Delhi 110001.
Das
Ruchika
R
Khastgir
Udayan
U
Goswami
Utpal
U
Arch Gen Psychiatry. 1991 Oct;48(10):891-8
1929758
Schizophr Res. 1991 Jan-Feb;4(1):23-30
2009253
Schizophr Bull. 1987;13(2):261-76
3616518
Schizophr Bull. 1986;12(3):447-59
3764361
Psychopharmacol Bull. 1992;28(3):297-302
1480733
Arch Gen Psychiatry. 1989 Aug;46(8):745-53
2665688
J Nerv Ment Dis. 1985 Jun;173(6):353-7
3998720
J Nerv Ment Dis. 1983 Jul;171(7):435-43
6864202
J Abnorm Psychol. 1989 Nov;98(4):341-56
2687342
Arch Gen Psychiatry. 1987 Jan;44(1):36-44
3800582
Am J Psychiatry. 1984 Feb;141(2):196-201
6691479
Psychiatry Res. 1979 Jul;1(1):9-16
233155
Arch Gen Psychiatry. 1977 Jun;34(6):633-44
326215
Acta Psychiatr Scand Suppl. 1970;212:11-9
4917967
J Neuropsychiatry Clin Neurosci. 1993 Summer;5(3):241-53
8369632
Br J Psychiatry. 1979 Apr;134:382-9
444788
Arch Gen Psychiatry. 1982 Mar;39(3):251-9
6978119
Am J Psychiatry. 1982 Sep;139(9):1127-30
6126128
Schizophr Res. 1995 Sep;17(1):1-3
8541242
Arch Gen Psychiatry. 1987 Nov;44(11):1008-14
3675128
Psychiatry Res. 1985 Jul;15(3):163-73
3862152
Schizophr Res. 1997 May 3;25(1):1-10
9176922
Am J Psychiatry. 1982 May;139(5):565-70
6122380
Acta Psychiatr Scand. 1974;50(4):425-62
4423855
Arch Gen Psychiatry. 1986 Feb;43(2):114-24
3947207
Biol Psychiatry. 1979 Aug;14(4):677-98
226189